Biotechnology company
Appears in 1 story · Last updated Nov 15, 2026
Acquired by Pfizer in November 2025
Pfizer has agreed to let Blackstone Life Sciences pay up to $1.5 billion of the development costs for berobenatide, an experimental weight-loss drug injected once a month. The money covers as many as 10 Phase 3 trials through 2028. Pfizer keeps full control of the program and gives up no ownership of the drug.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
